TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
8.61
-0.03 (-0.35%)
At close: Dec 5, 2025, 4:00 PM EST
8.75
+0.14 (1.63%)
After-hours: Dec 5, 2025, 4:10 PM EST

TransCode Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2018
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2018
Selling, General & Admin
5.465.957.158.43.40.44
Upgrade
Research & Development
11.589.7112.2610.232.750.28
Upgrade
Operating Expenses
17.0515.6619.4218.636.150.73
Upgrade
Operating Income
-17.05-15.66-19.42-18.63-6.15-0.73
Upgrade
Interest Expense
-0.01-0.03-0.06-0.03-0.1-0.39
Upgrade
Interest & Investment Income
000.010.0200
Upgrade
Currency Exchange Gain (Loss)
0.12-0.06----
Upgrade
Other Non Operating Income (Expenses)
-10.2-1.010.921.08-0.59-1.22
Upgrade
EBT Excluding Unusual Items
-27.13-16.76-18.55-17.56-6.84-2.34
Upgrade
Gain (Loss) on Sale of Assets
00---0-
Upgrade
Pretax Income
-27.13-16.75-18.55-17.56-6.84-2.34
Upgrade
Net Income
-27.13-16.75-18.55-17.56-6.84-2.34
Upgrade
Net Income to Common
-27.13-16.75-18.55-17.56-6.84-2.34
Upgrade
Shares Outstanding (Basic)
00----
Upgrade
Shares Outstanding (Diluted)
00----
Upgrade
EPS (Basic)
-58.12-1317.42----
Upgrade
EPS (Diluted)
-58.12-1317.42----
Upgrade
Free Cash Flow
-14.52-13.36-18.11-15.86-5.52-0.49
Upgrade
Free Cash Flow Per Share
-31.10-1050.30----
Upgrade
EBITDA
-17-15.57-19.3-18.54-6.11-
Upgrade
D&A For EBITDA
0.040.090.120.10.04-
Upgrade
EBIT
-17.05-15.66-19.42-18.63-6.15-0.73
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.